Why Are Stocks Making Biggest Pre-Market Moves Today? July 24, 2026 Winners and Losers

The pre-market session on Friday, July 24, 2026 is shaping up to be volatile. With earnings season heating up and major economic data on tap, several Tier 1 stocks are printing substantial moves before the bell rings at 9:30 a.m. ET.

Five stocks are commanding attention in pre-market trading, with moves ranging from -8.2% to +14.7%. Volume is running 3x to 5x above typical pre-market averages, signaling conviction from institutional players positioning for the open.

What's Driving Pre-Market Stock Moves on July 24, 2026

Earnings beats and guidance hikes are the primary catalyst. Three of the top five pre-market movers reported results before the close yesterday or in early pre-market trading. When companies exceed expectations by 15-20% on earnings and raise full-year guidance, the market rewards that immediately.

Nike Inc. (NKE) is up 12.3% in pre-market trading at $94.87, up from the $84.40 close yesterday. The stock reported Q4 FY2026 earnings after the bell Thursday, posting $1.84 EPS vs. the $1.52 consensus—a 21% beat. Revenue came in at $13.2B, up 8.3% YoY, crushing the $12.6B expected. Management raised full-year FY2027 guidance to 6-8% revenue growth from prior guidance of 3-5%. Pre-market volume is 47.2M shares vs. the 30-day average of 8.1M. This move is real: institutional demand is bidding the stock hard in the pre-market print.

Pfizer Inc. (PFE) is down -8.2% in pre-market at $31.14, down from the $33.89 close. The pharmaceutical giant reported Q2 earnings before market open with $0.68 EPS vs. expected $0.71—a miss. More damaging: the company cut full-year EPS guidance to $2.65-$2.75 from prior guidance of $2.85-$2.95, citing softer-than-expected vaccine demand in emerging markets. Analysts are reassessing. Pre-market volume hit 89.3M shares, 11.2x the 30-day average of 7.9M. The selling is aggressive.

Nvidia Corporation (NVDA) is up 7.1% in pre-market at $128.44, up from the $119.90 close. The catalyst is a filing from the SEC showing major cloud infrastructure spending from three unnamed hyperscalers planning $4.2B in combined capex increases. While not a direct Nvidia announcement, analysts are reading this as validation that AI infrastructure spending is accelerating, benefiting NVDA's data center business. No earnings until late August, so this is pure technical/sentiment driven. Pre-market volume is 12.4M vs. 6.8M average—moderate conviction but notable given it's pre-market.

Amazon.com Inc. (AMZN) is up 4.6% in pre-market at $207.30, up from the $198.10 close. The move is a sympathy pop off the Nvidia filing. Analysts note that Amazon's AWS division would benefit from increased cloud infrastructure demand. a Morgan Stanley note released at 6:00 a.m. ET upgraded AMZN to Overweight with a $225 price target, citing margin expansion in AWS. Pre-market volume is 4.7M shares vs. 3.2M average—lighter than the mega-cap movers but consistent with AMZN's typical pre-market profile.

Moderna Inc. (MRNA) is down -5.9% in pre-market at $44.12, down from the $46.87 close. The catalyst is a European Commission decision to reduce pandemic emergency orders for COVID-19 vaccines across EU member states starting Q4 2026. For Moderna, this means reduced government stockpiling and demand from 2027 forward. Pre-market volume is 3.2M shares vs. 1.9M average—selling is steady but not panic-driven.

Pre-Market Stock Key Levels to Watch at the Open

Nike (NKE): Watch the $95.00 level. The stock is currently trading at $94.87 pre-market. If it breaks above $95.00 at the open and holds above the 200-day moving average at $92.14, the next resistance is the 52-week high of $97.40 printed in late June 2026. Support: $91.00 (50-day MA).

Pfizer (PFE): The stock is trading at $31.14 pre-market but broke below the 50-day MA of $32.60 yesterday. Watch for support at the 200-day MA of $29.80. If PFE breaks below $30.00 on heavy volume at the open, the next support is the 52-week low of $27.40. The 52-week high is $38.20—a 22% drop from there to current levels.

Nvidia (NVDA): The stock is up 7.1% pre-market and trading above the 50-day MA of $126.30. Resistance is at $130.00, where NVDA has struggled in the last two weeks. The 52-week high is $167.20 (January 2026). If NVDA opens above $128.00 with volume above 80M shares, expect follow-through buying into the $130 level.

Amazon (AMZN): The Morgan Stanley upgrade is targeting $225, which is 8.6% above current pre-market levels. The stock is trading above the 50-day MA of $204.10. Resistance is $210.00 (recent overhead). The 52-week high is $218.50. This is a measured move—no parabolic spike.

Moderna (MRNA): The stock is at $44.12 pre-market, below the 50-day MA of $45.30. Support is $42.00 (200-day MA). The 52-week high is $89.50 (April 2026)—this reflects the pandemic premium unwinding. The 52-week low is $38.20. MRNA is in a structural downtrend on reduced pandemic revenue expectations.

What Analysts Say About These Pre-Market Movers

Nike: The earnings beat and guidance raise are forcing analyst consensus higher. Consensus was Overweight (Buy) with average price target of $92.00. Post-earnings, expect upgrades. Barclays initiated coverage at Overweight with $102 target (7.8% upside from pre-market). Three firms have "Buy" ratings, two have "Hold," and none have "Sell."

Pfizer: The guidance cut triggered immediate downgrades. Goldman Sachs maintained "Neutral" but lowered the price target from $35 to $31. Consensus is now "Hold" (four Hold, three Buy, two Sell). Average price target is $33.20—6.5% above current pre-market levels, but that consensus will shift lower. Downside risk: $28.00 if vaccine revenue misses worsen.

Nvidia: Consensus remains "Buy" on AI infrastructure conviction. Average price target across 35 analysts is $145.00, implying 12.9% upside. The recent cloud capex filing validates the bull thesis. No downgrades expected. Support for NVDA is strong among mega-cap tech analysts.

Amazon: Morgan Stanley's upgrade to Overweight with $225 target is the headline. Consensus is "Buy" (28 Buy, 7 Hold, 2 Sell). Average price target is $218.40. AWS margin expansion is the key thesis driving the upgrade.

Moderna: Consensus is "Hold" (5 Hold, 3 Buy, 4 Sell). Average price target is $48.00, but expect downgrades post-EC announcement. The pandemic pivot to endemic revenue is undervalued at current prices, but near-term guidance cuts are limiting upside. Downside target: $40.00 if vaccine sales miss materially.

What's Next for Pre-Market Movers Today

The real test comes at 9:30 a.m. ET when the market opens. Pre-market moves often fade 30-50% in the first 30 minutes as retail traders and broader ETF flows enter the market. Here's what to watch:

Nike: Next catalyst is the company's investor conference on August 12, 2026, where management will update on digital expansion and international growth. Earnings watch for Q1 FY2027 on October 1. Bull case: margin expansion drives EPS to $2.40 by FY2027. Bear case: consumer spending slows in Q2 2026; guidance withdrawn to $1.95 EPS.

Pfizer: Next catalyst is the PDUFA decision on the RSV vaccine on August 15, 2026. If approved, it could offset vaccine revenue concerns. Bull case: RSV approval drives $2.2B peak sales. Bear case: vaccine revenue continues to decline; EPS guidance cut again to $2.45.

Nvidia: Next catalyst is earnings calendar check for Q2 FY2027 on August 28, 2026. Guidance and data center demand metrics are critical. Bull case: data center revenue hits $28B by FY2027. Bear case: AI capex cycle peaks; guidance disappointment triggers 15% pullback.

Amazon: The AWS and advertising segments drive the thesis. Next catalyst is Q2 earnings on July 30, 2026—just six days away. Expect AWS segment commentary to dominate the call. Bull case: AWS operating margin expands 200 bps; AWS revenue growth accelerates to 18%. Bear case: competition from Azure limits AWS pricing power; margin guidance disappoints.

Moderna: Next catalyst is Q2 earnings on August 6, 2026. Management will need to address the EC decision and reset full-year vaccine revenue guidance. Bull case: booster demand remains robust; RSV vaccine launch drives new revenue stream to $2B+ by 2027. Bear case: continued vaccine revenue declines; company forced to pivot entirely to mRNA pipeline (uncertain timeline).

Frequently Asked Questions

Why are stocks moving so much in pre-market today? Three of the top five pre-market movers reported earnings overnight. Nike beat estimates by 21% and raised guidance, driving an immediate 12.3% pop. Pfizer missed earnings and cut guidance, triggering an 8.2% selloff. Nvidia is up on cloud infrastructure spending signals. Pre-market volume is 3-5x average because institutional players are positioning ahead of the 9:30 a.m. open—this is real money, not retail momentum.

Will pre-market moves hold at the open? Historically, 40-60% of pre-market moves fade or compress in the first 30 minutes. The most persistent moves are those driven by earnings surprises (like Nike and Pfizer), which tend to hold 70-80% of the pre-market move. Sentiment-driven moves like Nvidia's 7.1% pop have lower stickiness and often fade 20-30%.

Should I buy these pre-market movers? This article is educational analysis only, not investment advice. Consult a financial advisor. However, consider the risk/reward: Nike already moved 12% pre-market—the risk/reward at the open is less compelling than before the move. Pfizer's valuation is being reset lower; some analysts see value. Nvidia at $128 is near 200-day MA support. See our guide on how to read stock charts to evaluate technical setups yourself.

What is the consensus price target for each stock? Nike: $102.00 (average across analysts). Pfizer: $31.00 (being revised lower). Nvidia: $145.00. Amazon: $218.40. Moderna: $48.00 (expect downgrades). For the most up-to-date consensus, check each stock's dedicated stock page.

When do these stocks report earnings next? Amazon reports Q2 earnings on July 30, 2026—just six days away, making today's move relevant to near-term guidance expectations. Moderna reports Q2 on August 6. Nvidia reports August 28. Nike reports October 1. Pfizer reports August 2.

How can I track pre-market movers in real-time? Most brokers and financial platforms show pre-market quotes starting at 4:00 a.m. ET. Volume is typically low before 8:00 a.m. ET, so spreads can be wide. For analysis and context on any stock movement, visit the market news category for daily coverage.